Recurrent Ovarian High Grade Serous Adenocarcinoma Clinical Trials

7 clinical trials for Recurrent Ovarian High Grade Serous Adenocarcinoma across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer — RECRUITING · PHASE1
• Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer — RECRUITING · PHASE1
• IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer — RECRUITING · PHASE1
• Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer — WITHDRAWN · PHASE1
• Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy — WITHDRAWN · PHASE2

Refine this search